Navigation Links
Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
Date:2/28/2008

MORRISTOWN, N.J., Feb. 28 /PRNewswire/ -. Actavis Group, the international generic pharmaceuticals company, has received approval for Irinotecan Hydrochloride Injection from the U.S. Food & Drug Administration. Distribution of the product will begin immediately.

Irinotecan Hydrochloride Injection, the generic equivalent to Pfizer's Camptosar(R) will be available in 40 mg/2 mL and 100 mg/ 5 mL sizes and is used in the treatment of patients with metastatic carcinoma of the colon or rectum. Annual sales of Irinotecan Hydrochloride Injection in the United States were approximately US$556 million for the twelve months ending December 2007 according to IMS Health data.

Doug Boothe, Executive Vice President of US Commercial & Administration, said: "The launch of Irinotecan marks the expansion of Actavis' US portfolio into the injectable pharmaceuticals arena. Actavis has set its sights firmly on the hospital sector and currently has around 300 pending applications worldwide for injectable medicines. Furthermore, Actavis' ambitious pipeline comprises more than 60 new injectable projects, developed both internally and through established relationships with other developers."

Actavis currently markets over 50 hospital products worldwide, with a focus on oncology products and a growing range of anti-infectives, local anesthetics and analgesics.

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at http://www.actavis.us.

Information in this press release may c
'/>"/>

SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
6. IsoTis Receives FDA Clearance for Accell Family of Products
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... basic Naltrexone HCL information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:10/30/2014)... 2014 Rancho BioSciences , the ... manually curated public data source TCGA for ... the data is now available for other oncology groups. ... and internal data sources for their Pharma, Government and ... the data that becomes more easily accessible. Rancho ...
(Date:10/30/2014)... York, NY (PRWEB) October 30, 2014 ... plan for its ICH Stability Testing and Package Test ... this investment centers on a dramatic increase in environmental ... volume of stability, storage and aging samples to be ... stage of this major capital expenditure has already taken ...
(Date:10/30/2014)... Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a company overview at the Nomura ... ET in Boston, MA. ... the "Investors & Media" section of the Company,s website, ... website within 48 hours and will be archived for a ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... Oct. 26, 2011 Accuray Incorporated (Nasdaq: ... announced today significant momentum in global adoption of its ... are now in use at leading cancer centers throughout ... image-guided, intensity-modulated radiation therapy (IG-IMRT) for routine radiation therapy ...
... poison from this smorgasbord of recent salmonella outbreaks in ... That,s in 2011 alone, and the list goes on, ... Prevention. But perhaps not for long, thanks to a ... of salmonella bacteria before contaminated food or animals reach ...
... ProteinSimple today announced the launch of the ... Imaging platforms. Bot1 automates analysis of protein aggregates and ... the IBC,s 11th Annual Formulation Strategy for Protein Therapeutics ... Protein therapeutic manufacturers must monitor microscopic particles and ...
Cached Biology Technology:Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode 2Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode 3Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode 4ProteinSimple Automates Aggregation Analysis 2
(Date:10/30/2014)... NY, October 30, 2014—Oligonucleotide-based therapeutics present unique challenges ... cause reproductive and developmental harm. New consensus guidelines ... combined chemical and biological characteristics of these novel ... , a peer-reviewed journal from Mary Ann ... free on the Nucleic Acid Therapeutics ...
(Date:10/30/2014)... | Heidelberg, 30 October 2014 Biological membranes are ... understanding of adsorption of solution ions onto lipid ... Now, a new study provides a quantitative description ... solution ions. Joanna Kotyńska and Zbigniew Figaszewski from ... of a study describing these findings, just published ...
(Date:10/29/2014)... their hair as a consequence of chemotherapy will benefit ... scalp cooling technology that prevents hair loss. , The ... by global scalp cooling manufacturing company, Paxman Coolers, of ... of the University of Huddersfield. , The research will ... a background in the pharmacology of cancer treatment, which ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Ion adsorption matter in biology 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... Marine Board-ESF published its 13th Position Paper, which presents ... needed to assess the effects of anthropogenic sound upon ... Board Position Paper 13 results from the activities and ... marine mammals convened at the joint European Marine Board ...
... gorgeously-decorated fish which throng Australia,s coral reefs and help earn ... be written in their genes. Of particular importance may ... re-colonise regions of reef devastated by global warming and other ... says Dr Line Bay of the ARC Centre of Excellence ...
... base and,revenues, JERICHO, N.Y., Sept. 29 ... it has executed a non-binding,Letter of Intent with ... controlling interest in Biometric Solutions, Inc. The terms ... Biometric Solutions LLC is a premiere engineering firm, ...
Cached Biology News:Effects of anthropogenic sound on marine mammals -- a research strategy 2Fishy future written in the genes 2Fishy future written in the genes 3bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC 2bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC 3
Pronase Reagent...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: